Financial Reporting Schedule - Orion Corporation will publish its Financial Statement Release for 2025 on Thursday, 12 February 2026 [1] - The Interim Reports and Half-Year Financial Report for 2026 will be published on the following dates: - Interim Report for January-March 2026: Thursday, 23 April 2026 - Half-Year Financial Report for January-June 2026: Friday, 17 July 2026 - Interim Report for January-September 2026: Wednesday, 28 October 2026 [1] Annual General Meeting - The Annual General Meeting is scheduled for Tuesday, 24 March 2026 [2] Company Overview - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience, focusing on developing, manufacturing, and marketing human and veterinary pharmaceuticals and active pharmaceutical ingredients [2] - The company has a diverse portfolio that includes proprietary and generic medicines as well as consumer health products, with core therapy areas in oncology and pain [2] - In 2024, Orion's net sales reached EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] - Orion's A and B shares are listed on Nasdaq Helsinki [2]

图片来源：Joe Raedle/Getty Images Chewy在全美拥有17个配送中心，宣称能够为80%的人口提供次日达服务，为近乎100%的人口提供两日 达服务。其药房配送中心数量较少，但已构建起覆盖全国的配送网络，且具备进一步扩张的潜力。 根据美国兽医协会（AVMA）的数据，美国拥有超3.4万家兽医诊所，且呈现出分散态势。毕马威 （KPMG）估计，全美约30%的兽医诊所为私募股权公司拥有，20%为企业持有，剩余50%多为独立诊 所。其中规模最大的几家企业包括Mars Veterinary Health、National Veterinary Associates、SVP & MVP、Thrive Pet Healthcare和Petco，其在美国的兽医诊所数量从约300家到2000多家不等。这意味着 Chewy在这一领域尚处于起步阶段。 Chewy向兽医护理和药房领域的扩张，使其有望在蓬勃发展的宠物健康市场中占据更大份额。美国银行 估计，随着公司扩大诊所规模并提高药房服务渗透率，有望新增逾10亿美元收入。这无疑是值得深耕的 大市场。 美国人对宠物的宠爱催生了规模庞大的产业。2024年，美国家庭仅在兽 ...

$VET has launched StarGate, which is their highly anticipated new way of staking $VET in the ecosystem.That's why there's a 6-month early reward window. Some key features:- Up to 9% APY- Only 10K VET ($200) required to join- Rewards are paid every 7 days- $10 million in bonuses will be distributed in the coming 6 monthsFundamentally, #VeChain has been building massively in the last six months; it's just a matter of time until price starts to pick up momentum.VeChain (@vechainofficial):By all measures, week ...

🚀 Poloniex New Listing $VELVET @velvet_capital✅ Deposit open on July 16th, 07:30 (UTC)✅ Full trading enable on July 16th, 09:30 (UTC)Details: https://t.co/U4IblU9M3m https://t.co/BmOCuit87J ...

（原标题：和讯投顾张培准:横盘整理不改上行趋势,证券板块有望向上挑战更高高度） 7月14日，和讯投顾张培准称，今天周一，上证指数继续沿5天均线上攻，短期上涨趋势未变，价格突破3500后继续向更高点挑战，这一轮上涨目 标先看3600或3700，摸到3700概率较大，之后可能在3700点附近横盘整理再选择方向。上证指数仍可继续看涨。中小板、创业板今天回落回踩5天 均线，但仍是强势上升格局。中证1000指数上周五中阴线后今天横盘整理。领涨板块中，人形机器人因周末利好消息，部分公司收到实打实订 单，板块指数走势稳健，目前1800点下方空间有限，上方看到2000点有10%涨幅，板块个股涨幅可能在10%至30%，强势个股能涨30%，该板块调 整已有四五个多月，指数在60天均线附近横盘整理后向上突破，当下值得高度关注，机会不少。电力板块突破前期横盘压制区域，到1300点后继 续上攻，上行趋势未变，走势稳健，上涨后横盘再继续向上，电力板块中强势个股可继续持有。医药板块走势分化，指数从2050张到2200后形成 双头，前期张幅较大的个股已出现明显获利回吐，若板块指数从2200回调至60均线附近，将是更好的买点，当下医药板块中保 ...

根据市场公开信息及7月11日披露的机构调研信息，知名私募翼虎投资近期对1家上市公司进行了调研， 相关名单如下： 1）阳光诺和 （翼虎投资参与公司特定对象调研&线上会议） 调研纪要：阳光诺和是一家专业的药物临床前及临床综合研发服务CRO，致力于协助国内医药制造企 业加速实现进口替代和自主创新。公司建设iCVETide多肽新药发现平台，携手华为云打造多肽分子发 现平台，拥有缓控释改良型新药平台，团队由200多人的国际化高层次科技创业团队组成。STC008注射 液适应症为晚期实体瘤的肿瘤恶液质，市场潜力巨大，预计2032年全球市场规模达40亿美元。公司在经 皮递送（贴剂）研发平台方面经验丰富，已成功验证多个产品工艺，与日本KNEK公司合作引进先进透 皮贴剂技术。公司有3个品种4个适应症处于临床研究阶段，包括STC007的术后镇痛和尿毒症瘙痒适应 症，STC008的肿瘤恶病质适应症。 机构简介： 深圳市翼虎投资管理有限公司成立于2006年11月10日，注册资本为1000万元，翼虎投资系国内知名阳光 私募基金，中国证券投资基金业协会会员，具新财富最佳分析师、中国证券业金牛分析师、卖方分析师 水晶球奖评选投票权、并获中国 ...

Group 1: Market Performance - Energy sector ETFs rose by 2.69%, while semiconductor ETFs increased by 1.33%. Other sectors such as biotechnology, regional banks, and the banking sector saw gains of at least 0.7%, whereas consumer discretionary ETFs fell by 0.34%, internet stock indices dropped by 0.77%, and financial sector ETFs decreased by 0.89% [1] - In the S&P 500 energy sector, companies like Devon Energy, Halliburton, APA, Occidental Petroleum, Hess Corporation, and Baker Hughes saw increases of at least 4.21%, with Diamondback Energy ranking fifth among Nasdaq 100 constituents [1] Group 2: ETF Details - Energy ETF closed at $88.50, up by 2.68%, with a total market value of $22.163 billion, reflecting a year-to-date increase of 4.97% [2] - Semiconductor ETF closed at $283.48, up by 1.33%, with a total market value of $3.351 billion, showing a year-to-date increase of 17.06% [2] - Biotechnology ETF closed at $129.33, up by 0.94%, with a total market value of $10.269 billion, down by 2.09% year-to-date [2] - Regional bank ETF closed at $63.15, up by 0.91%, with a total market value of $5.270 billion, reflecting a year-to-date increase of 6.06% [2] - Banking sector ETF closed at $58.46, up by 0.69%, with a total market value of $4.525 billion, showing a year-to-date increase of 6.87% [2] - Consumer discretionary ETF closed at $217.66, down by 0.34%, with a total market value of $27.339 billion, reflecting a year-to-date decrease of 2.51% [2] - Financial sector ETF closed at $52.21, down by 0.89%, with a total market value of $58.112 billion, showing a year-to-date increase of 8.79% [2]

ACQUISITION TO MATERIALLY INCREASE NAMEPLATE PROCESSING CAPACITY POTENTIAL TO UNLOCK ADDITIONAL VALUE THROUGH OPTIMISATION AND EXPANSION OF PURCHASING NETWORK MONTREAL, July 08, 2025 (GLOBE NEWSWIRE) -- Dynacor Group Inc. (TSX: DNG) (“Dynacor” or the "Corporation"), is pleased to announce it has signed a share purchase agreement to acquire Arkham Metals SAS (Ecuador) from Pelorus Minerals Limited, a wholly owned subsidiary of Arkham Metals Limited Australia. As previously announced, Dynacor will pay $9.75 m ...

Share it: @Nickelodeon @NickelodeonFamilyClick HERE to download assetsNEW YORK, July 8, 2025 /PRNewswire/ -- Nickelodeon has added the hit animated series Unicorn Academy™ and Vida the Vet™, from Spin Master Entertainment, to its programming lineup beginning July. This marked the series' respective linear debuts in the U.S.--Unicorn Academy on Nickelodeon and Vida the Vet on the Nick Jr. channel. Vida the Vet Still Unicorn Academy Key Art The fantasy-adventure series Unicorn Academy follows Sophia an ...

Company Overview and Strategy - VolitionRx focuses on advancing low-cost, early detection, and treatment monitoring tests in cancer and sepsis[7] - The company's strategy involves licensing its IP to major players, following a low CapEx/low OpEx model similar to its Nu.Q® Vet business[11, 20] - Volition aims to be cash neutral on a full-year basis in 2025, balancing income with expenditure[87] Veterinary Commercial Progress - The Nu.Q® Vet Cancer test is available in over 20 countries[20] - Approximately 120,000 Nu.Q® Vet Cancer tests and test components were sold in 2024[20, 39] - The company has received $23 million in upfront and milestone payments to date, with an additional $5 million milestone payment anticipated in 2025[20] Expansion into Human Diagnostics - Volition is targeting licensing deals in the human sepsis and cancer space in 2025[10] - The company sees a $4 billion opportunity in lung cancer screening, prognostics, and MRD, and a $1 billion+ opportunity in sepsis testing and monitoring[21] - First revenue was recorded for CE-marked product in Q1 2025[85] Financial Performance - Volition recorded approximately $0.25 million in revenue in Q1 2025, a 44% increase over the first quarter of the prior year[87] - Net cash used in operating activities averaged $1.4 million a month, almost 50% lower than the first quarter of 2024[87]